scholarly journals The relationship between body mass index and estimated glomerular filtration rate

2020 ◽  
Vol 45 (4) ◽  
pp. 133-139
Author(s):  
Marija Klačar ◽  
Marija Zarić ◽  
Jagoda Popović
Keyword(s):  
Body Mass Index ◽  
Renal Function ◽  
Body Mass ◽  
Filtration Rate ◽  
Estimated Glomerular Filtration Rate ◽  
Estimated Gfr ◽  
Normal Body ◽  
The Mean ◽  
The Relationship ◽  
Reduced Renal Function

INTRODUCTION: The increasing prevalence of chronic kidney disease (CKD) is a major health problem. The prevalence of obesity has also been rapidly increasing worldwide. Few studies have examined the relationship between excess body weight and CKD risk. Aim: To evaluate the possible contribution of increased body mass index (BMI) to impaired renal function in the general population sample. METHODS: The study involved 500 participants older than 30 years (228 men, 272 women, age 57.58±13.68) who visited their general practitioner in Health Center "Dr Simo Milošević". Blood samples, blood pressure anthropometric measures were performed on each participant. Estimated glomerular filtration rate was calculated using the abbreviated equation from MDRD study ("the Modification of Diet in Renal Disease Study") and CKD was defined as eGFR less than 60 ml/min/1.73m². Statistical analysis was performed using SPSS 19.0 software (IBM, Somers, New York, USA). RESULTS: The mean BMI was 25.09±3.54 kg/m² with 0.6% in underweight (BMI<18.5 kg/m²), 17.6% in lower normal (BMI 18.5 to 21.9 kg/m²), 33.2% in upper normal (BMI 22.0 to 24.9 kg/m²) and 48.6% in overweight or obese (BMI>25.0 kg/m²) body mass category. The mean eGFR was 100.33±30.78 ml/min/1.73m² with 112±8.62 in underweight, 116.94±3.8 in lower normal, 102.37±2.39 in upper normal and 92.78±1.72 in overweight or obese category. Estimated GFR values decreased significantly with increasing BMI specially in those in upper normal compared to lower normal (p<0.001) and overweight and obese compared to lower normal body mass category (p<0.001). Compared with participants with lower normal body mass, the non-adjusted odds ratio (OR) for mildly or moderately reduced renal function (eGFR<90 ml/min/1.73m²) was 2.54 (95% CI 1.41-4.56) for upper normal and 3.26 (95% CI 1.88-5.70) for overweight and obese participants. After adjusting for potential confounding variables (age, sex, diabetes mellitus, hypertension, hypercholesterolemia, hypertriglyceridemia and smoking status) or for mildly or moderately reduced renal function was 2.23 (95% CI 1.21-4.10) for upper normal 2.65 (95% CI 1.44-4.87) for overweight or obese participants compared to those in lower normal body mass category. CONCLUSION: Estimated GFR values decreased significantly with increasing BMI specially in those in upper normal compared to lower normal (p<0.001) and overweight and obese compared to lower normal body mass category (p<0.001). This study showed that increasing BMI is strongly associated with decreasing eGFR in the general population. The underlying mechanism behind this association remains to be investigated through prospective population-based studies.

scholarly journals Relationship between Body Mass Index (BMI) and Glomerulus Filtration Rate Estimation in Overweight Students at the Health Analyst Department of Pontianak Health Polytechnic

2021 ◽  
Vol 2 (1) ◽  
pp. 27-33
Author(s):  
Slamet
Keyword(s):  
Body Mass Index ◽  
Glomerular Filtration Rate ◽  
Glomerular Filtration ◽  
Body Mass ◽  
Filtration Rate ◽  
Estimated Glomerular Filtration Rate ◽  
The Body ◽  
P Value ◽  
Fat Deposits ◽  
The Relationship

Obesity occurs due to excessive fat deposits in the body, one of which is a poor diet. The relationship between overweight and chronic kidney disease (CKD) is mediated through several mechanisms of adiponectin, leptin, and resistin, the development of inflammation, oxidative stress, abnormal lipid metabolism, and activation of the renin-angiotensin-aldosterone system. The purpose of this study was to determine the relationship between body mass index and estimated glomerular filtration rate in overweight students at the Health Analyst Department of Pontianak Health Polytechnic. The research design used was cross-sectional. This research was conducted on May 14-18, 2018. The population is a student health analyst. With the criteria for students from the 2015 and 2016 batches who are still active, BMI 23-29.9 Kg/m² and aged 18 to 22 years, totaling 37 respondents. The sampling technique used is total sampling. Performed include measurements of BMI, serum creatinine Jaffe method, fixed time and ELFG Cokroft-Gault formula. The results obtained using the Kendall's tau test showed that the p value (0.906) was greater than (0.05) meaning that there was no relationship between body mass index and estimated glomerular filtration rate in overweight students at the Health Analyst Department of Pontianak Health Polytechnic.

Abstract 6277: Predictive Value of Estimated Glomerular Filtration Rate for Cardiovascular Events: The Treating to New Targets Study

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
James Shepherd ◽  
Chuan-Chuan Wun ◽  
Daniel J Wilson ◽  
Andrea L Zuckerman
Keyword(s):  
Renal Function ◽  
Glomerular Filtration Rate ◽  
Glomerular Filtration ◽  
Cardiovascular Events ◽  
Filtration Rate ◽  
Estimated Glomerular Filtration Rate ◽  
Lipid Lowering ◽  
Final Visit ◽  
The Relationship ◽  
Dose Dependent

We previously demonstrated a dose-dependent improvement in renal function and reduction in cardiovascular risk in TNT with intensive lipid lowering with atorvastatin (ATV) 80 mg vs 10 mg. This post hoc analysis examines the relationship between the observed improvement in estimated glomerular filtration rate (eGFR) and reduction of major cardiovascular events (MCVE). After 8 weeks open-label therapy with ATV 10 mg, 10,001 patients with CHD were randomized to double-blind therapy with either ATV 10 or 80 mg. Patients were followed for a median of 4.9 years for the occurrence of MCVEs (CHD death, nonfatal MI, and stroke). The relationship between change from baseline eGFR (using the MDRD equation) at the final visit prior to a MCVE and the risk of MCVE was assessed using a Cox proportional hazards model adjusting for baseline eGFR and other baseline characteristics. Of 9656 patients with complete renal data, 156 had a MCVE before follow-up eGFR assessment and were excluded. In the remaining 9500 patients, mean baseline eGFR was 65.3 mL/min/1.73 m 2 and mean change from baseline was 4.3 mL/min/1.73 m 2 . This represented a reduction in the risk of MCVE of 2.7% per mL increase in eGFR (HR 0.973, 95% CI 0.967– 0.980, P <0.0001). This association remained significant in patients with eGFR <60 and those with eGFR ≥60 mL/min/1.73 m 2 at baseline, with no significant interaction between eGFR change and baseline renal status ( P =0.98). A 5 mL/min on-treatment improvement in eGFR was associated with a 12.6% reduction in MCVE, while a 5 mL/min reduction was associated with a 14.4% increase in MCVE. Mean change from baseline eGFR was 3.5 mL/min/1.73 m 2 with ATV 10 mg and 5.2 mL/min/1.73 m 2 with ATV 80 mg, representing significant 9.3% and 12.4% reductions in risk, respectively. Analysis of interaction between treatment and eGFR change for prediction of MCVE demonstrated a stronger association between eGFR change and MCVE in the ATV 80 mg treatment group ( P =0.011). Improvement in eGFR was highly associated with a reduction in MCVE, irrespective of baseline renal function. This relationship was dose dependent. Improvement in eGFR may be a biomarker for the response to atorvastatin, and for the stabilization of atherosclerotic cardiovascular disease.

Association of serum 25-hydroxy vitamin D and body mass index in cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 6625-6625
Author(s):  
D. Gupta ◽  
K. Trukova ◽  
P. G. Vashi ◽  
A. Adams ◽  
G. M. Lambert ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Vitamin D ◽  
Cancer Patients ◽  
Body Mass ◽  
Case Series ◽  
Spearman Correlation ◽  
Dietary Recommendations ◽  
25 Hydroxy Vitamin D ◽  
The Mean ◽  
The Relationship

6625 Background: The association between vitamin D and obesity remains unsettled with studies reporting conflicting findings on the relationship between the two. This association assumes even greater importance in cancer because of the alleged role of vitamin D in cancer risk and survival. Currently, the dietary recommendations for Vitamin D do not take into account a person's body mass index (BMI). We investigated the relationship between serum 25-hydroxy-vitamin D [25(OH)D] and BMI in a large sample of cancer patients. Methods: A consecutive case series of 740 cancer patients seen at Cancer Treatment Centers of America from Jan 08 to June 08. Serum 25(OH)D was measured at presentation to the hospital. The cohort was divided in 4 BMI groups (<18.5, 18.5–24.9, 25–29.9, and >30.0 kg/m2). Correlation between 25(OH)D and BMI was evaluated using Spearman correlation coefficient. Mean 25(OH)D was compared across the 4 BMI groups using ANOVA. Linear regression was used to quantify the relationship between BMI and 25(OH)D. Results: Of 740 patients, 303 were males and 437 females. The mean age at presentation was 55.7 years (SD = 10.2). The mean BMI was 27.9 kg/m2 (SD = 6.7). Most common cancers were lung (134, 18.1%), breast (131, 17.7%), colorectal (97, 13.1%), pancreas (86, 11.6%), prostate (45, 6.1%) and ovarian (39, 5.3%). The mean serum 25(OH)D was 21.9 ng/ml (SD = 13.5). Analysis revealed that as BMI groups increased from normal to overweight or obese classifications, there was a significant decrease in 25(OH)D (Table). The Spearman correlation between 25(OH)D and BMI was -0.20 (p = 0.001). Every 1 kg/m2 increase in BMI was significantly associated with a 0.43 ng/ml decline in serum 25(OH)D (p = 0.001). Conclusions: We found that obese cancer patients (BMI >=30 kg/m2) had significantly lower levels of serum 25(OH)D as compared to nonobese patients (BMI <30 kg/m2). BMI should be taken into account when assessing a patient's vitamin D status and more aggressive vitamin D supplementation should be considered in obese cancer patients. [Table: see text] No significant financial relationships to disclose.

scholarly journals The influence of a peritoneovenous shunt for cirrhotic and malignant intractable ascites on renal function

2018 ◽  
Vol 7 (3) ◽  
pp. 205846011876420 ◽  
Author(s):  
Takafumi Segawa ◽  
Kenichi Kato ◽  
Kazuya Kawashima ◽  
Tomohiro Suzuki ◽  
Shigeru Ehara
Keyword(s):  
Renal Function ◽  
Liver Cirrhosis ◽  
Renal Dysfunction ◽  
Filtration Rate ◽  
Estimated Glomerular Filtration Rate ◽  
Intractable Ascites ◽  
Peritoneovenous Shunt ◽  
Catheter Obstruction ◽  
Peritoneovenous Shunts ◽  
The Relationship

Background Peritoneovenous shunts (PVS) are widely used for palliation of intractable ascites caused by peritoneal carcinomatosis (PC) or liver cirrhosis (LC). Some patients who need PVS have renal dysfunction. However, renal dysfunction is considered a relative contraindication. Therefore, it is important to assess renal function before PVS placement. Purpose To evaluate the relationship between PVS and renal function. Material and Methods Between October 2007 and July 2015, 60 patients (PC = 47; LC = 10; others = 3) underwent PVS placement for intractable ascites. Changes in estimated glomerular filtration rate (eGFR) and other adverse events (AEs) were retrospectively analyzed. Results Changes in eGFR before, one day after, and one week after PVS placement could be evaluated in 46 patients. The median eGFR before, one day after, and one week after was 56.5, 59.1, and 64.7 mL/min/1.73 m2, respectively ( P < 0.05). These values were 61.6, 72, and 67.1 mL/min/1.73 m2, respectively, in PC patients (n = 34; P < 0.05) and 28.5, 27, and 37.2 mL/min/1.73 m2, respectively, in LC patients (n = 10; P < 0.05). In 17 patients with moderate to severe renal dysfunction (eGFR < 45), these values were 23.4, 23.7, and 30.5 mL/min/1.73 m2, respectively. The most frequent AE was PVS catheter obstruction, which occurred in 12 patients (20.7%). Clinical disseminated intravascular coagulation occurred in six patients (10.3%) and caused death in three patients (5.2%). Conclusion PVS placement for intractable ascites is associated with various AEs. However, PVS appeared to promote renal function, especially in patients with renal impairment.

scholarly journals The relationship between body mass index before pregnancy and the amount of weight that should be gained during pregnancy: A cross-sectional study

2019 ◽  
Vol 35 (5) ◽  
Author(s):  
Resmiye Özdilek ◽  
Yılda Arzu Aba ◽  
Sena Dilek Aksoy ◽  
Bulat Aytek Şık ◽  
Yaşam Kemal Akpak
Keyword(s):  
Body Mass Index ◽  
Weight Gain ◽  
Pregnant Women ◽  
Body Mass ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
The Mean ◽  
The Relationship

Objective: To investigate the adaptation of pregnant women to the recommended weight gain range according to body mass index (BMI) and to determine the factors affecting them. Methods: This cross-sectional study was performed in a university hospital’s obstetrics and gynecology unit (tertiary center) in Turkey. This study was conducted between March 2018 and August 2018 (6 months) in pregnant women. Pregnant women with chronic disease and receiving treatment during antenatal follow-up, with twin pregnancy, with a fetus with a congenital abnormality, and nutritional disturbance were excluded from the study. Eight hundred twelve pregnant women with normal antenatal follow-up and who volunteered to participate were included in the study. Results: The mean age of the participants was 27.66±5.05 years. The mean weight and BMI before pregnancy were near standard in all participants. The group with the highest rate of recommended weight gain according to BMI before pregnancy was the group with low weight pregnant women. The ideal weight gain rate in all groups was 32%. Conclusions: The groups with overweight and obese pregnant women according to BMI before pregnancy had the highest rates of weight gain, above the recommended limits. BMI before pregnancy directly affects weight gain during pregnancy and the importance of pre-pregnancy counseling and weight loss is emphasized once again. doi: https://doi.org/10.12669/pjms.35.5.133 How to cite this:Ozdilek R, Aba YA, Aksoy SD, Sik BA, Akpak YK. The relationship between body mass index before pregnancy and the amount of weight that should be gained during pregnancy: A cross-sectional study. Pak J Med Sci. 2019;35(5):---------.  doi: https://doi.org/10.12669/pjms.35.5.133 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

scholarly journals Perspectives Concerning the Influence of Protein Intake for Renal Function in Diabetic Nephropathy

2021 ◽  
Vol 3 (1) ◽  
pp. 7-10
Author(s):  
Kato Y ◽  
Kato Y ◽  
Bando H
Keyword(s):  
Renal Function ◽  
Diabetic Nephropathy ◽  
Kidney Disease ◽  
Protein Intake ◽  
Filtration Rate ◽  
Diabetic Kidney Disease ◽  
American Diabetes Association ◽  
Estimated Glomerular Filtration Rate ◽  
Protein Restriction ◽  
The Relationship

Regarding the diet treatment of diabetic nephropathy, protein restriction has been recommended. American Diabetes Association (ADA) proposed protein restriction guidelines in the 2008 edition. However, this comment was deleted in the 2013/2019 edition, because of insufficient evidence. A recent report showed that the intake of plant protein has a protective effect on the decrease of estimated glomerular filtration rate (eGFR), and the intake of animal protein has neither protection nor deterioration. There are controversies about the relationship between protein intake and the reduction of renal function. Further research will be expected for diabetic nephropathy, diabetic kidney disease (DKD), and chronic kidney disease (CKD).

scholarly journals Body Mass Index and the Relationship with Chronic Kidney Disease in a Tertiary Care Hospital in Romania

2016 ◽  
Vol 62 (2) ◽  
pp. 225-229
Author(s):  
Carmen Denise Caldararu ◽  
Dorin Tarta ◽  
Raluca Pop ◽  
Mirela Gliga ◽  
Emilian Carasca ◽  
...  
Keyword(s):  
Risk Factors ◽  
Body Mass Index ◽  
Chronic Kidney Disease ◽  
Glomerular Filtration Rate ◽  
Kidney Disease ◽  
Glomerular Filtration ◽  
Body Mass ◽  
Filtration Rate ◽  
Overweight And Obesity ◽  
The Relationship

AbstractObesity and chronic kidney disease are epidemic size. Chronic kidney disease (CKD) appears to be more common in obese, although interrelation is not supported by all authors.Aim: The aim of the study was to investigate the effects of overweight and obesity on glomerular filtration rate (GFR) and the relationship between body mass index (BMI) and other risk factors for CKD.Methods: This is a cross-sectional study on 627 patients admitted in a Nephrology Department between January 2007 - December 2011. Patients were divided according to eGFR in a CKD group and a non-CKD group. Patients were divided based on BMI in: normal (<25 kg/m2), overweight (≥ 25 kg/m2 and ≤30 kg/m2) and obese (>30 kg/m2). Demographical, clinical and laboratory data (serum creatinine, lipid parameters, etc) were used for the statistical analysis. The relationship between BMI (as a marker of obesity and overweight), glomerular filtration rate and other possible risk factors for chronic kidney disease was studied.Results: 43.70% patients were obese and 33.17% overweight. CKD prevalence was 58.69%. Logistic regression analysis showed that systolic blood pressure was the main determinant of CKD in our patients.Conclusion: Lack of association between BMI and CKD was demonstrated in our study.

Estimated Glomerular Filtration Rate Changes In Patients (Pts) With Chronic Myeloid Leukemia (CML) Treated With Tyrosine Kinase Inhibitors (TKI)

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 1488-1488 ◽  
Author(s):  
Musa Yilmaz ◽  
Hagop M. Kantarjian ◽  
Alfonso Quintas-Cardama ◽  
Susan O'Brien ◽  
Jan A. Burger ◽  
...  
Keyword(s):  
Renal Failure ◽  
Renal Function ◽  
Glomerular Filtration Rate ◽  
Research Funding ◽  
Filtration Rate ◽  
Estimated Glomerular Filtration Rate ◽  
Estimated Gfr ◽  
Free Survival ◽  
Tki Treatment

Abstract Introduction TKI are standard therapy for pts with CML. Although generally safe, they are associated with some adverse events, most of them manageable and transient. Renal dysfunction has been reported anecdotally on pts with CML treated with TKI. We investigated the incidence of acute renal failure (ARF) and chronic renal failure (CRF) among the CML pts treated with TKI, and analyzed possible relationship between treatment duration with TKI and changes in estimated glomerular filtration rate (GFR). Methods Four hundred and seventy-five pts treated with imatinib (255 pts; 49 at 400 mg daily; 206 at 800 mg daily), dasatinib (101 pts) and nilotinib (119 pts) in prospective clinical trials at a single institution were evaluated. Pts were followed routinely with blood chemistries including renal function tests, at least weekly during the first 2-3 months, then every 2-4 weeks for 6-12 months, then every 8-12 weeks. GFR was estimated using the Modification of Diet in Renal Disease (MDRD) equation and recorded from the onset of TKI treatment until last follow up. ARF was defined as an increase in serum creatinine of ≥0.3 mg/dl, and CRF defined as an estimated GFR ≤ 60 ml/min/1.73 m2 persisting for at least 90 days. Results After a median follow-up of 50 months (range, 2 to 138 months), 19 pts (4%) developed ARF. The median time of onset for ARF was 9 days (range 4-84 days). Sixteen of 19 pts (84%) were on imatinib, 2 on nilotinib, and 1 on dasatinib (p=0.006). There was no association between imatinib dose and incidence of ARF (2% with 400mg vs 7% with 800mg) (p=0.174). The median age for pts with ARF was 58 yrs compared to 48 for pts with no ARF (p=0.009). Seventy-nine percent (15 out of 19) of ARF pts and 59% (269 of 456) of pts without ARF were male (p=0.063). During study time, estimated GFR decreased significantly in pts treated with imatinib compared to dasatinib (Figure 1) (p<0.001). Interestingly, in pts treated with nilotinib, we observed significant increase in GFR when we compare baseline GFR to the GFR in all other time points (p<0.05). 442 pts (94%) had no CRF at baseline, and 48 of these pts (11%) developed CRF over the course of TKI treatment. Among them, 39 pts (81%) were on imatinib compared to 19% on other TKIs (5 dasatinib, 4 nilotinib) (p<0.001). There was no association between imatinib dose (400mg and 800mg) and CRF incidence (p=0.591). The median age for pts who developed CRF was 61 yrs compared to 47 for those with no CRF (p=<0.001). Fifty-eight percent (28 out of 48) of CRF pts and 60 % (256 of 427) of pts without CRF were male (p=0.828). Overall CCyR rate was the same (89%) in pts who had ARF and no ARF, and overall MMR rate was 79% in pts with ARF and 83% in pts with no ARF (p=0.401). Overall CCyR rate was 98% in pts who developed CRF over the course of TKI therapy compared to 89% in pts who did not develop CKD (p=0.026). Similarly, overall MMR rate was higher (96%) in pts developed CKD compared to pts who did not have CKD (82%) (p=0.013). Overall survival and transformation free survival was not statistically different when compared pts with ARF vs no ARF and CRF vs no CRF. However, pts with ARF had decreased event free survival (EFS) when compared to no ARF pts (p=0.019). There was no EFS difference in CRF pts (0.966). Conclusion Long-term treatment with imatinib may cause a significant decline in estimated GFR. Interestingly, treatment with nilotinib may cause a slight improvement in GFR. It is important that pts are monitored for renal function during therapy with TKI, with particular attention to those with risk factors for renal dysfunction. Disclosures: Ravandi: Pfizer and Novartis: Honoraria; BMS: Research Funding. Jabbour:Novartis, BMS, Ariad, and Pfizer: Consultancy. Cortes:Ariad, BMS, Novartis, Pfizer and Teva: Research Funding; BMS, Pfizer and Teva. : Consultancy.

Sign in / Sign up

Export Citation Format

Share Document